bluebird bio, Inc.

( )
BLUE PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
AMGNAmgen, Inc. 0.48%246.731.5%$893.73m
MRNAModerna, Inc. 3.73%155.540.0%$852.62m
VRTXVertex Pharmaceuticals, Inc. 0.58%288.981.9%$508.85m
GILDGilead Sciences, Inc. -0.03%62.341.0%$477.30m
NVAXNovavax, Inc. 12.49%64.2975.7%$468.89m
REGNRegeneron Pharmaceuticals, Inc. 0.20%596.562.6%$452.80m
ILMNIllumina, Inc. 1.04%193.023.3%$357.64m
SNSSSunesis Pharmaceuticals, Inc. 3.00%3.780.7%$264.24m
BIIBBiogen, Inc. 0.93%212.581.8%$245.16m
BNTXBioNTech SE 2.24%161.030.0%$215.97m
CRSPCRISPR Therapeutics AG 10.68%70.600.6%$192.52m
BMRNBioMarin Pharmaceutical, Inc. 1.62%86.364.2%$117.47m
EXASEXACT Sciences Corp. 7.95%44.4017.7%$102.51m
NTLAIntellia Therapeutics, Inc. 16.98%63.182.2%$99.79m
AXSMAxsome Therapeutics, Inc. 1.40%41.211.8%$99.33m

Company Profile

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.